Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2024-2028

Report
160 Pages
December 2023
Region: Global
TechNavio
ID: 5918145

The castration-resistant prostate cancer (CRPC) treatment market is forecasted to grow by USD 5.98 bn during 2023-2028, accelerating at a CAGR of 8.83% during the forecast period. The report on the castration-resistant prostate cancer (CRPC) treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of prostate cancer, rising research and development (r and d) efforts in CRPC treatment, and increasing awareness of prostate cancer diagnosis.

The castration-resistant prostate cancer (CRPC) treatment market is segmented as below:

By Distribution Channel

Hospital pharmacies
Retail pharmacies
Online pharmacies

By Therapy

Hormonal therapy
Chemotherapy
Others

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the evolving CRPC treatment options as one of the prime reasons driving the castration-resistant prostate cancer (CRPC) treatment market growth during the next few years. Also, convenience and availability of oral medications and focus on advanced healthcare infrastructure will lead to sizable demand in the market.

The report on the castration-resistant prostate cancer (CRPC) treatment market covers the following areas:

Castration-resistant prostate cancer (CRPC) treatment market sizing
Castration-resistant prostate cancer (CRPC) treatment market forecast
Castration-resistant prostate cancer (CRPC) treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading castration-resistant prostate cancer (CRPC) treatment market vendors that include Active Biotech AB, Allarity Therapeutics Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Everest Pharmaceuticals Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson, Medias Klinikum GmbH and Co. KG, Merck KGaA, Novartis AG, Pfizer Inc., Robotic Prostate Centre Cambridge, Sanofi SA, The Focal Therapy Clinic, and Ono Pharmaceutical Co. Ltd.. Also, the castration-resistant prostate cancer (CRPC) treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 06: Executive Summary - Chart on Market Segmentation by Therapy
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global castration-resistant prostate cancer (CRPC) treatment market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global castration-resistant prostate cancer (crpc) treatment market 2018 - 2022 ($ billion)
4.2 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion)
4.3 Therapy Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Therapy Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Distribution Channel

6.1 Market segments
Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
6.2 Comparison by Distribution Channel
Exhibit 32: Chart on Comparison by Distribution Channel
Exhibit 33: Data Table on Comparison by Distribution Channel
6.3 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
6.4 Retail pharmacies - Market size and forecast 2023-2028
Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
6.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Distribution Channel
Exhibit 46: Market opportunity by Distribution Channel ($ billion)
Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ billion)

7 Market Segmentation by Therapy

7.1 Market segments
Exhibit 48: Chart on Therapy - Market share 2023-2028 (%)
Exhibit 49: Data Table on Therapy - Market share 2023-2028 (%)
7.2 Comparison by Therapy
Exhibit 50: Chart on Comparison by Therapy
Exhibit 51: Data Table on Comparison by Therapy
7.3 Hormonal therapy - Market size and forecast 2023-2028
Exhibit 52: Chart on Hormonal therapy - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on Hormonal therapy - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on Hormonal therapy - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Hormonal therapy - Year-over-year growth 2023-2028 (%)
7.4 Chemotherapy - Market size and forecast 2023-2028
Exhibit 56: Chart on Chemotherapy - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Chemotherapy - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Chemotherapy - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Chemotherapy - Year-over-year growth 2023-2028 (%)
7.5 Others - Market size and forecast 2023-2028
Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Therapy
Exhibit 64: Market opportunity by Therapy ($ billion)
Exhibit 65: Data Table on Market opportunity by Therapy ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share by geography 2023-2028 (%)
Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 China - Market size and forecast 2023-2028
Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
9.9 Canada - Market size and forecast 2023-2028
Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.10 Germany - Market size and forecast 2023-2028
Exhibit 99: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.11 UK - Market size and forecast 2023-2028
Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity by geography
Exhibit 107: Market opportunity by geography ($ billion)
Exhibit 108: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 Active Biotech AB
Exhibit 115: Active Biotech AB - Overview
Exhibit 116: Active Biotech AB - Product / Service
Exhibit 117: Active Biotech AB - Key offerings
12.4 Allarity Therapeutics Inc.
Exhibit 118: Allarity Therapeutics Inc. - Overview
Exhibit 119: Allarity Therapeutics Inc. - Product / Service
Exhibit 120: Allarity Therapeutics Inc. - Key offerings
12.5 Amgen Inc.
Exhibit 121: Amgen Inc. - Overview
Exhibit 122: Amgen Inc. - Product / Service
Exhibit 123: Amgen Inc. - Key offerings
12.6 Amneal Pharmaceuticals Inc.
Exhibit 124: Amneal Pharmaceuticals Inc. - Overview
Exhibit 125: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 126: Amneal Pharmaceuticals Inc. - Key news
Exhibit 127: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 128: Amneal Pharmaceuticals Inc. - Segment focus
12.7 Astellas Pharma Inc.
Exhibit 129: Astellas Pharma Inc. - Overview
Exhibit 130: Astellas Pharma Inc. - Product / Service
Exhibit 131: Astellas Pharma Inc. - Key news
Exhibit 132: Astellas Pharma Inc. - Key offerings
12.8 Bayer AG
Exhibit 133: Bayer AG - Overview
Exhibit 134: Bayer AG - Business segments
Exhibit 135: Bayer AG - Key news
Exhibit 136: Bayer AG - Key offerings
Exhibit 137: Bayer AG - Segment focus
12.9 BeiGene Ltd.
Exhibit 138: BeiGene Ltd. - Overview
Exhibit 139: BeiGene Ltd. - Business segments
Exhibit 140: BeiGene Ltd. - Key offerings
Exhibit 141: BeiGene Ltd. - Segment focus
12.10 Dr Reddys Laboratories Ltd.
Exhibit 142: Dr Reddys Laboratories Ltd. - Overview
Exhibit 143: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 144: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 145: Dr Reddys Laboratories Ltd. - Segment focus
12.11 F. Hoffmann La Roche Ltd.
Exhibit 146: F. Hoffmann La Roche Ltd. - Overview
Exhibit 147: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 148: F. Hoffmann La Roche Ltd. - Key news
Exhibit 149: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 150: F. Hoffmann La Roche Ltd. - Segment focus
12.12 Johnson and Johnson
Exhibit 151: Johnson and Johnson - Overview
Exhibit 152: Johnson and Johnson - Business segments
Exhibit 153: Johnson and Johnson - Key news
Exhibit 154: Johnson and Johnson - Key offerings
Exhibit 155: Johnson and Johnson - Segment focus
12.13 Merck KGaA
Exhibit 156: Merck KGaA - Overview
Exhibit 157: Merck KGaA - Business segments
Exhibit 158: Merck KGaA - Key news
Exhibit 159: Merck KGaA - Key offerings
Exhibit 160: Merck KGaA - Segment focus
12.14 Novartis AG
Exhibit 161: Novartis AG - Overview
Exhibit 162: Novartis AG - Business segments
Exhibit 163: Novartis AG - Key offerings
Exhibit 164: Novartis AG - Segment focus
12.15 Ono Pharmaceutical Co. Ltd.
Exhibit 165: Ono Pharmaceutical Co. Ltd. - Overview
Exhibit 166: Ono Pharmaceutical Co. Ltd. - Product / Service
Exhibit 167: Ono Pharmaceutical Co. Ltd. - Key offerings
12.16 Pfizer Inc.
Exhibit 168: Pfizer Inc. - Overview
Exhibit 169: Pfizer Inc. - Product / Service
Exhibit 170: Pfizer Inc. - Key news
Exhibit 171: Pfizer Inc. - Key offerings
12.17 Sanofi SA
Exhibit 172: Sanofi SA - Overview
Exhibit 173: Sanofi SA - Business segments
Exhibit 174: Sanofi SA - Key news
Exhibit 175: Sanofi SA - Key offerings
Exhibit 176: Sanofi SA - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 177: Inclusions checklist
Exhibit 178: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 179: Currency conversion rates for US$
13.4 Research methodology
Exhibit 180: Research methodology
Exhibit 181: Validation techniques employed for market sizing
Exhibit 182: Information sources
13.5 List of abbreviations
Exhibit 183: List of abbreviations

List of Exhibits

Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market by Geography
Exhibits 5: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 6: Executive Summary - Chart on Market Segmentation by Therapy
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global castration-resistant prostate cancer (crpc) treatment market 2018 - 2022 ($ billion)
Exhibits 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion)
Exhibits 20: Historic Market Size - Therapy Segment 2018 - 2022 ($ billion)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Distribution Channel
Exhibits 33: Data Table on Comparison by Distribution Channel
Exhibits 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 46: Market opportunity by Distribution Channel ($ billion)
Exhibits 47: Data Table on Market opportunity by Distribution Channel ($ billion)
Exhibits 48: Chart on Therapy - Market share 2023-2028 (%)
Exhibits 49: Data Table on Therapy - Market share 2023-2028 (%)
Exhibits 50: Chart on Comparison by Therapy
Exhibits 51: Data Table on Comparison by Therapy
Exhibits 52: Chart on Hormonal therapy - Market size and forecast 2023-2028 ($ billion)
Exhibits 53: Data Table on Hormonal therapy - Market size and forecast 2023-2028 ($ billion)
Exhibits 54: Chart on Hormonal therapy - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on Hormonal therapy - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on Chemotherapy - Market size and forecast 2023-2028 ($ billion)
Exhibits 57: Data Table on Chemotherapy - Market size and forecast 2023-2028 ($ billion)
Exhibits 58: Chart on Chemotherapy - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Chemotherapy - Year-over-year growth 2023-2028 (%)
Exhibits 60: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibits 61: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibits 62: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits 64: Market opportunity by Therapy ($ billion)
Exhibits 65: Data Table on Market opportunity by Therapy ($ billion)
Exhibits 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 67: Chart on Market share by geography 2023-2028 (%)
Exhibits 68: Data Table on Market share by geography 2023-2028 (%)
Exhibits 69: Chart on Geographic comparison
Exhibits 70: Data Table on Geographic comparison
Exhibits 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibits 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibits 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibits 92: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibits 93: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibits 96: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibits 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits 100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits 101: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 103: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits 104: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits 105: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 107: Market opportunity by geography ($ billion)
Exhibits 108: Data Tables on Market opportunity by geography ($ billion)
Exhibits 109: Impact of drivers and challenges in 2023 and 2028
Exhibits 110: Overview on Criticality of inputs and Factors of differentiation
Exhibits 111: Overview on factors of disruption
Exhibits 112: Impact of key risks on business
Exhibits 113: Vendors covered
Exhibits 114: Matrix on vendor position and classification
Exhibits 115: Active Biotech AB - Overview
Exhibits 116: Active Biotech AB - Product / Service
Exhibits 117: Active Biotech AB - Key offerings
Exhibits 118: Allarity Therapeutics Inc. - Overview
Exhibits 119: Allarity Therapeutics Inc. - Product / Service
Exhibits 120: Allarity Therapeutics Inc. - Key offerings
Exhibits 121: Amgen Inc. - Overview
Exhibits 122: Amgen Inc. - Product / Service
Exhibits 123: Amgen Inc. - Key offerings
Exhibits 124: Amneal Pharmaceuticals Inc. - Overview
Exhibits 125: Amneal Pharmaceuticals Inc. - Business segments
Exhibits 126: Amneal Pharmaceuticals Inc. - Key news
Exhibits 127: Amneal Pharmaceuticals Inc. - Key offerings
Exhibits 128: Amneal Pharmaceuticals Inc. - Segment focus
Exhibits 129: Astellas Pharma Inc. - Overview
Exhibits 130: Astellas Pharma Inc. - Product / Service
Exhibits 131: Astellas Pharma Inc. - Key news
Exhibits 132: Astellas Pharma Inc. - Key offerings
Exhibits 133: Bayer AG - Overview
Exhibits 134: Bayer AG - Business segments
Exhibits 135: Bayer AG - Key news
Exhibits 136: Bayer AG - Key offerings
Exhibits 137: Bayer AG - Segment focus
Exhibits 138: BeiGene Ltd. - Overview
Exhibits 139: BeiGene Ltd. - Business segments
Exhibits 140: BeiGene Ltd. - Key offerings
Exhibits 141: BeiGene Ltd. - Segment focus
Exhibits 142: Dr Reddys Laboratories Ltd. - Overview
Exhibits 143: Dr Reddys Laboratories Ltd. - Business segments
Exhibits 144: Dr Reddys Laboratories Ltd. - Key offerings
Exhibits 145: Dr Reddys Laboratories Ltd. - Segment focus
Exhibits 146: F. Hoffmann La Roche Ltd. - Overview
Exhibits 147: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 148: F. Hoffmann La Roche Ltd. - Key news
Exhibits 149: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 150: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 151: Johnson and Johnson - Overview
Exhibits 152: Johnson and Johnson - Business segments
Exhibits 153: Johnson and Johnson - Key news
Exhibits 154: Johnson and Johnson - Key offerings
Exhibits 155: Johnson and Johnson - Segment focus
Exhibits 156: Merck KGaA - Overview
Exhibits 157: Merck KGaA - Business segments
Exhibits 158: Merck KGaA - Key news
Exhibits 159: Merck KGaA - Key offerings
Exhibits 160: Merck KGaA - Segment focus
Exhibits 161: Novartis AG - Overview
Exhibits 162: Novartis AG - Business segments
Exhibits 163: Novartis AG - Key offerings
Exhibits 164: Novartis AG - Segment focus
Exhibits 165: Ono Pharmaceutical Co. Ltd. - Overview
Exhibits 166: Ono Pharmaceutical Co. Ltd. - Product / Service
Exhibits 167: Ono Pharmaceutical Co. Ltd. - Key offerings
Exhibits 168: Pfizer Inc. - Overview
Exhibits 169: Pfizer Inc. - Product / Service
Exhibits 170: Pfizer Inc. - Key news
Exhibits 171: Pfizer Inc. - Key offerings
Exhibits 172: Sanofi SA - Overview
Exhibits 173: Sanofi SA - Business segments
Exhibits 174: Sanofi SA - Key news
Exhibits 175: Sanofi SA - Key offerings
Exhibits 176: Sanofi SA - Segment focus
Exhibits 177: Inclusions checklist
Exhibits 178: Exclusions checklist
Exhibits 179: Currency conversion rates for US$
Exhibits 180: Research methodology
Exhibits 181: Validation techniques employed for market sizing
Exhibits 182: Information sources
Exhibits 183: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global castration-resistant prostate cancer (CRPC) treatment market: Active Biotech AB, Allarity Therapeutics Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Everest Pharmaceuticals Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson, Medias Klinikum GmbH and Co. KG, Merck KGaA, Novartis AG, Pfizer Inc., Robotic Prostate Centre Cambridge, Sanofi SA, The Focal Therapy Clinic, and Ono Pharmaceutical Co. Ltd..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is evolving CRPC treatment options.'

According to the report, one of the major drivers for this market is the increasing prevalence of prostate cancer.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Active Biotech AB
Allarity Therapeutics Inc.
Amgen Inc.
Amneal Pharmaceuticals Inc.
Astellas Pharma Inc.
Bayer AG
BeiGene Ltd.
Daiichi Sankyo Co. Ltd.
Dr Reddys Laboratories Ltd.
Everest Pharmaceuticals Ltd.
F. Hoffmann La Roche Ltd.
Johnson and Johnson
Medias Klinikum GmbH and Co. KG
Merck KGaA
Novartis AG
Pfizer Inc.
Robotic Prostate Centre Cambridge
Sanofi SA
The Focal Therapy Clinic
Ono Pharmaceutical Co. Ltd.

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2418EUR$2,500USD£2,072GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€3868EUR$4,000USD£3,315GBP

The castration-resistant prostate cancer (CRPC) treatment market is segmented as below:

By Distribution Channel

By Therapy

By Geography

The report on the castration-resistant prostate cancer (CRPC) treatment market covers the following areas:

Table of Contents

Executive Summary

Companies Mentioned (Partial List)

Related Topics

Related Reports

Castrate-Resistant Prostate Cancer Market Report and Forecast 2024-2032

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Prostate Cancer Drugs Global Market Report 2024

Prostate Cancer Therapeutics Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type, End User, and Geography

Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032